N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride: structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 10380472 |
| CHEMBL ID | 5095032 |
| SCHEMBL ID | 40976 |
| MeSH ID | M0553500 |
| Synonym |
|---|
| 909910-22-1 |
| mem 3454 |
| mem3454 |
| rg3487 |
| rg-3487 |
| SCHEMBL40976 |
| O6J463N18M , |
| n-((3s)-1-azabicyclo(2.2.2)oct-3-yl)-1h-indazole-3-carboxamide hydrochloride |
| facinicline hydrochloride |
| 1h-indazole-3-carboxamide, n-(3s)-1-azabicyclo(2.2.2)oct-3-yl-, hydrochloride (1:1) |
| mem-3454 |
| 1h-indazole-3-carboxamide, n-(3s)-1-azabicyclo(2.2.2)oct-3-yl-, monohydrochloride |
| 677305-02-1 |
| unii-o6j463n18m |
| n-[(3s)-1-azabicyclo[2.2.2]oct-3-yl]-1h-indazole-3-carboxamide hydrochloride |
| Q27285409 |
| facinicline hcl |
| 677305-02-1(hcl) |
| MS-24446 |
| facinicline (hydrochloride) |
| HY-108057A |
| CS-0081613 |
| n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-3-carboxamide;hydrochloride |
| AKOS040749293 |
| CHEMBL5095032 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| quinuclidines | quinuclidines; saturated organic heterobicyclic parent | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| thiophenes | mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound | non-polar solvent | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| indazoles | indazole | 2011 | 2017 | 9.5 | high | 1 | 0 | 0 | 0 | 6 | 0 | ||
| isoxazoles | isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| pnu 120596 | ureas | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cognition Disorders | 0 | 2014 | 2014 | 10.0 | high | 1 | 0 | 0 | 0 | 1 | 0 | |
| Dementia Praecox | 0 | 2014 | 2014 | 10.0 | high | 1 | 0 | 0 | 0 | 1 | 0 | |
| Schizophrenia | 1 | 2014 | 2014 | 10.0 | high | 1 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology, , Volume: 231, Issue:10 | 2014 |